SIMPONI ARIA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for SIMPONI ARIA (SIMPONI ARIA).
Golimumab is a human IgG1κ monoclonal antibody that binds to and neutralizes tumor necrosis factor alpha (TNF-α), preventing its interaction with p55 and p75 cell surface TNF receptors. This reduces pro-inflammatory cytokine production and immune cell activation.
| Metabolism | Golimumab is a monoclonal antibody; metabolism is via catabolic pathways to small peptides and amino acids. No specific metabolic enzymes are involved. |
| Excretion | Primarily degraded into small peptides and amino acids via reticuloendothelial system; negligible renal (0.1%) and fecal (<1%) excretion; no significant biliary elimination. |
| Half-life | Terminal elimination half-life approximately 10-13 days (mean 12 days), allowing for every 2-week dosing after initial loading regimen. |
| Protein binding | Approximately 82% bound to serum proteins (albumin); non-specific binding to immunoglobulins. |
| Volume of Distribution | Approximately 0.1 L/kg (central volume); limited extravascular distribution due to high molecular weight (monoclonal antibody distribution mostly confined to vascular space). |
| Bioavailability | Bioavailability:- Intravenous: 100%.- Subcutaneous: Not applicable (Simponi Aria is IV only; subcutaneous formulation (Simponi) is ~53% bioavailable). |
| Onset of Action | Intravenous infusion: Clinical response (ACR20) observed as early as 2 weeks; peak effect at 4-6 weeks. |
| Duration of Action | Sustained clinical effect over 2-week dosing interval; recommended infusion frequency every 8 weeks after loading doses. |
2 mg/kg intravenous infusion over 30 minutes at weeks 0 and 4, then every 8 weeks thereafter.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required for renal impairment; specific GFR-based guidelines are not established. |
| Liver impairment | No dose adjustment recommended for mild to moderate hepatic impairment; use with caution in severe hepatic impairment (Child-Pugh class C) as safety data are limited. |
| Pediatric use | For active polyarticular juvenile idiopathic arthritis in patients 2 years and older: 2 mg/kg IV at weeks 0 and 4, then every 8 weeks. |
| Geriatric use | No specific dose adjustment recommended; use with caution due to higher incidence of infections and decreased renal/hepatic function with age. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for SIMPONI ARIA (SIMPONI ARIA).
| Breastfeeding | Golimumab is excreted in human breast milk in low amounts, with a milk-to-plasma ratio of approximately 0.002. The low bioavailability of oral immunoglobulin G suggests minimal systemic absorption in the nursing infant. However, the clinical significance is unknown. Caution is advised; consider the benefits of breastfeeding and the potential for adverse effects in the infant, including immune suppression and risk of infection. |
| Teratogenic Risk | SIMPONI ARIA (golimumab) is a monoclonal antibody (IgG1) that crosses the placenta in increasing amounts during the second and third trimesters, with fetal levels reaching maternal levels at birth. Based on animal studies and limited human data, there is no clear evidence of teratogenicity in the first trimester. However, fetal B-cell depletion and increased risk of infection have been observed in infants exposed in utero during the second and third trimesters. Live vaccines should be avoided in infants for up to 6 months after birth if maternal exposure occurred after the first trimester. |
■ FDA Black Box Warning
Increased risk of serious infections, including tuberculosis, bacterial sepsis, invasive fungal infections, and opportunistic infections, which may lead to hospitalization or death. Malignancies, including lymphoma, have been reported.
| Serious Effects |
["Known hypersensitivity to golimumab or any component of the formulation","Active infections, including clinically localized infections"]
| Precautions | ["Serious infections: screen for latent TB before initiation; monitor for active TB during therapy; consider discontinuing if serious infection develops.","Malignancies: rare cases of lymphoma and other malignancies reported; risk may be higher than in the general population.","Hepatitis B reactivation: screen HBV carriers; discontinue if reactivation occurs.","Congestive heart failure: may worsen or precipitate new-onset CHF; use with caution.","Demyelinating disorders: rare reports of new-onset or exacerbation of CNS demyelinating disease.","Hematologic cytopenias: monitor for signs of pancytopenia; consider discontinuation if significant abnormalities occur."] |
Loading safety data…
| Fetal Monitoring | Maternal monitoring: Complete blood count, liver function tests, and monitoring for signs of infection or allergic reactions. Fetal/neonatal monitoring: Infants exposed in utero during the second or third trimester should be monitored for immunosuppression, including B-cell counts, and live vaccines should be delayed until at least 6 months of age. No specific fetal monitoring outside standard obstetric care. |
| Fertility Effects | Golimumab has no known direct effects on fertility in animal studies. However, chronic inflammatory conditions (e.g., rheumatoid arthritis) for which this drug is used may themselves impair fertility. The drug's effect on human fertility has not been systematically studied. |